Raymond James Financial Inc. Purchases Shares of 313,787 Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Raymond James Financial Inc. acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 313,787 shares of the company's stock, valued at approximately $6,015,000. Raymond James Financial Inc. owned approximately 0.40% of Viridian Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the company. Lord Abbett & CO. LLC acquired a new position in Viridian Therapeutics in the 3rd quarter worth about $8,917,000. JPMorgan Chase & Co. grew its stake in shares of Viridian Therapeutics by 218.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company's stock valued at $9,108,000 after buying an additional 274,641 shares in the last quarter. Barclays PLC increased its holdings in Viridian Therapeutics by 113.1% in the third quarter. Barclays PLC now owns 125,397 shares of the company's stock worth $2,851,000 after buying an additional 66,550 shares during the last quarter. Principal Financial Group Inc. raised its position in Viridian Therapeutics by 1,603.4% during the third quarter. Principal Financial Group Inc. now owns 172,810 shares of the company's stock valued at $3,931,000 after acquiring an additional 162,665 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in Viridian Therapeutics by 89.1% in the fourth quarter. SG Americas Securities LLC now owns 31,085 shares of the company's stock valued at $596,000 after acquiring an additional 14,644 shares during the last quarter.

Viridian Therapeutics Stock Performance

NASDAQ VRDN traded up $0.37 during trading on Wednesday, hitting $13.55. The company's stock had a trading volume of 580,850 shares, compared to its average volume of 1,197,332. Viridian Therapeutics, Inc. has a 52 week low of $9.90 and a 52 week high of $27.20. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.11 billion, a P/E ratio of -3.14 and a beta of 0.81. The firm has a 50 day moving average price of $14.05 and a 200 day moving average price of $18.07.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, beating analysts' consensus estimates of ($1.05) by $0.24. The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Equities research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. HC Wainwright restated a "buy" rating and set a $34.00 price target on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Needham & Company LLC restated a "buy" rating and set a $38.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $35.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.